GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opus Genetics Inc (NAS:IRD) » Definitions » FCF Yield %

IRD (Opus Genetics) FCF Yield % : -31.51 (As of Apr. 02, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Opus Genetics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Opus Genetics's Trailing 12-Month Free Cash Flow is $-13.59 Mil, and Market Cap is $43.13 Mil. Therefore, Opus Genetics's FCF Yield % for today is -31.51%.

The historical rank and industry rank for Opus Genetics's FCF Yield % or its related term are showing as below:

IRD' s FCF Yield % Range Over the Past 10 Years
Min: -57.12   Med: -26.58   Max: 39.25
Current: -31.51


During the past 5 years, the highest FCF Yield % of Opus Genetics was 39.25%. The lowest was -57.12%. And the median was -26.58%.

IRD's FCF Yield % is ranked worse than
65.89% of 1498 companies
in the Biotechnology industry
Industry Median: -15.56 vs IRD: -31.51

Opus Genetics's FCF Margin % for the quarter that ended in Sep. 2024 was -132.66%.


Opus Genetics FCF Yield % Historical Data

The historical data trend for Opus Genetics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opus Genetics FCF Yield % Chart

Opus Genetics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
- -9.62 -27.56 19.44 -1.54

Opus Genetics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.86 25.21 -45.34 -73.38 -59.79

Competitive Comparison of Opus Genetics's FCF Yield %

For the Biotechnology subindustry, Opus Genetics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Opus Genetics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opus Genetics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Opus Genetics's FCF Yield % falls into.


;
;

Opus Genetics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Opus Genetics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-1.112 / 72.17077
=-1.54%

Opus Genetics's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-5.13 * 4 / 34.31938
=-59.79%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Opus Genetics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Opus Genetics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Opus Genetics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Opus Genetics Business Description

Traded in Other Exchanges
Address
37000 Grand River Avenue, Suite 120, Farmington Hills, MI, USA, 48335
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Executives
George Magrath officer: Chief Executive Officer 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Ronil A. Patel officer: SVP, Operations & Bus. Dev. 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Mina Sooch director, officer: President and CEO 17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Manuso James S J director 5130 ROUTE 212, WILLOW NY 12495
Jay Pepose director 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Susan Benton director 3916 VALRICO GROVE DRIVE, VALRICO FL 33594
Rabourn Amy Zaremba officer: VP of Finance 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Cam Gallagher director 6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Alan R Meyer director
Sean Ainsworth director 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Bernhard Hoffmann officer: VP of Corp. Dev. & Ops & Sec. 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Lara Sullivan director C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Ben Gil Price director 8297 CHAMPIONS GATE BLVD. #444, CHAMPIONS GATE FL 33896
Douglas J Swirsky officer: President and CFO C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Lisa Nolan officer: Chief Business Officer 36 ROCKLAND MILLS, ROCKLAND DE 19732